No Signal — Quality Gated

The directional consensus did not pass the post-analysis signal-quality review.

Weak multi-run short spread 6.2 had no baseline regime alignment (neutral).

LLY

LLY

NYSENO SIGNAL · QUALITY GATED
CompletedRe-run
Swing · Multi-day confirmation3 Models · Analysis Snapshot: Aug 26, 2026, 2:11 PM · Valid for ~12h
NO SIGNAL — QUALITY GATEDQuarantined
Consensus was scored, but no signal was emitted.· Candidate only
1 Long2 Short
Candidate levels · not emitted
Stop$1235.00
Entry$1215.00
Target$1177.00
No signal was created

Weak multi-run short spread 6.2 had no baseline regime alignment (neutral).

Evidence spread reviewed from 6.2 to 6.2.

LowConditionalHigh
Key Disagreement
  • Mistral-Large-2512 (62% LONG) argues for a bullish swing trade, citing a confluence of support at $1206.94, the 50-day SMA, and high-volume nodes, whereas the invalidation criteria focus on the risk of a breakdown below this same level.
Bear Case(2 models)
67%

Both models highlight that LLY has lost its 4-hour SMA20 ($1229) and triggered a bearish MACD zero-cross, indicating that momentum has rolled over following a 2% session decline. Clear relative weakness against a flat SPY and negative alignment with XLV/TLT suggest that a breach of the $1206.94 support shelf is imminent. If this level fails, the models project a further slide toward the value-area low near $1141 or the volume-profile POC cluster at $1187 over the next 1-3 weeks.

Bull Case(3 models)
33%

All three models agree that LLY is at a high-probability entry point as it tests critical support at $1206.94, which aligns with the 50-day SMA and a high-volume node cluster ($1187-$1205). Technical exhaustion is evident via a deeply oversold 30-minute RSI (24.07) and price action below the lower Bollinger Band, signaling a mean-reversion opportunity toward resistance at $1234-$1240. The case is bolstered by strong fundamentals, including 48% revenue growth and raised guidance, alongside cross-asset confirmation from XLV and TLT for a 1-3 week swing trade.

What Would Invalidate
  • The short thesis is invalidated by a 4h reclaim and close above the $1234.07 resistance level, which recovers the value-area core and SMA 20.
  • A breakdown and 4h close below the $1206.94 support level invalidates the bullish thesis, signaling a potential test of the $1176.97 zone.

Individual Model Analysis

Claude Opus 4.8 FastDeep
Analysis Outcome
SHORT
1.90R·48% confidence
Ensemble signal levelslimit entry
Entry
$1215.00
Target
$1177.00
Stop
$1235.00
Bull/Bear CompetitionWinner: BEAR
Bear 48%Δ 4%Bull 44%
Bear Case

LLY lost its 4h SMA20 and printed a bearish MACD zero-cross with falling RSI, signaling momentum has rolled over from the 52-week high after the -2% session. A break of 4h support at $1206.94 opens a path toward the volume-profile POC/HVN cluster near $1187, with healthcare (XLV) and the rates proxy (TLT) confirming the down move. The setup works if sellers force acceptance below the depressed-volume support shelf and drive price back to the value-area core.

Bull Case

LLY is testing 4h support $1206.94 and the 30-day POC/HVN cluster ($1205-1187) after a 2% pullback, with 30-min RSI at 24 (oversold, below lower Bollinger) signaling near-term selling exhaustion into a defined support shelf. The setup matches the exact "favor support retests" mechanism that produced 3 consecutive wins on this symbol, and defensive Beta 0.51 plus confirming XLV/TLT cross-asset read-through support a bounce back toward the $1234 resistance. Expected path: stabilization at support and mean-reversion rally over 1-3 weeks targeting the 4h resistance zone.

42s
DeepSeek V4 FlashFast
Analysis Outcome
SHORT
1.90R·59% confidence
Ensemble signal levelslimit entry
Entry
$1215.00
Target
$1177.00
Stop
$1235.00
Bull/Bear CompetitionWinner: BEAR
Bear 68%Δ 32%Bull 36%
Bear Case

LLY has broken below its 4h SMA20 ($1229) and triggered a bearish MACD zero-cross with accelerating downside momentum, now testing the $1206.94 support level. The stock is down 2% on the session while SPY is flat, showing clear relative weakness, and the breakdown is confirmed by sector (XLV -0.47%) and rates (TLT -0.35%) alignment. With the 4h RSI declining through 45 and no fresh catalyst to reverse the slide, a break below $1206 support opens a path toward the value-area low near $1141 and the 1day SMA50 at $1185 over the next 1-3 weeks.

Bull Case

LLY has pulled back to test the 4-hour support at $1206.94 after a sharp selloff, with the 30-minute RSI at 24.07 (deeply oversold) and price below the lower Bollinger band — extreme exhaustion levels that historically precede mean-reverting bounces. The stock remains in a strong fundamental uptrend with 48% revenue growth, raised full-year guidance, and a 3-for-0 prior long track record, while the pullback to the high-volume node near $1187 offers a favorable risk/reward entry for a swing mean-reversion back toward the $1234-$1240 resistance zone over 1-3 weeks.

1m 41s
Mistral Large 2512Balanced
Analysis Outcome
LONG
7.94R·62% confidence
market entry
Entry
$1208.95
Target
$1280.00
Stop
$1200.00
Bull/Bear CompetitionWinner: BULL
Bull 65%Δ 4%Bear 61%
Bull Case

LLY presents a compelling long setup as it tests a critical support zone amid a broader pullback, offering a high-probability entry for a swing trade. The stock is currently trading near the 4-hour support level of $1206.94, which aligns with the 50-day SMA ( $1200.58) and a high-volume node ( $1205.49) , suggesting strong buying interest at this level. With RSI on the 4-hour timeframe nearing oversold territory (45.69) and MACD showing signs of a potential bullish crossover, the technical setup favors a bounce toward the nearest resistance at $1234.07, with a potential extension toward $1280 if momentum accelerates. The recent earnings beat and raised guidance provide fundamental support, while cross-asset confirmation from the healthcare sector (XLV) and rates proxy (TLT) further bolster the case for a rebound.

Bear Case

LLY is positioned for a short swing trade due to its technical breakdown at a critical resistance zone and weakening momentum, despite strong fundamentals. The stock has failed to reclaim its 4h resistance at $1234.07, confirmed by a bearish MACD crossover and falling RSI (45.69), signaling a potential reversal from its recent overextension near the 52-week high ($1292.65). With no fresh catalysts or earnings events in the near term, the stock is vulnerable to profit-taking and mean reversion, especially as cross-asset confirmation from XLV and TLT aligns with a broader Healthcare sector pullback.

2m 40s